PT  - JOURNAL ARTICLE
AU  - Sulaiman, Imran
AU  - Chung, Matthew
AU  - Angel, Luis
AU  - Tsay, Jun-Chieh J.
AU  - Wu, Benjamin G.
AU  - Yeung, Stephen T.
AU  - Krolikowski, Kelsey
AU  - Li, Yonghua
AU  - Duerr, Ralf
AU  - Schluger, Rosemary
AU  - Thannickal, Sara A.
AU  - Koide, Akiko
AU  - Rafeq, Samaan
AU  - Barnett, Clea
AU  - Postelnicu, Radu
AU  - Wang, Chang
AU  - Banakis, Stephanie
AU  - Perez-Perez, Lizzette
AU  - Jour, George
AU  - Shen, Guomiao
AU  - Meyn, Peter
AU  - Carpenito, Joseph
AU  - Liu, Xiuxiu
AU  - Ji, Kun
AU  - Collazo, Destiny
AU  - Labarbiera, Anthony
AU  - Amoroso, Nancy
AU  - Brosnahan, Shari
AU  - Mukherjee, Vikramjit
AU  - Kaufman, David
AU  - Bakker, Jan
AU  - Lubinsky, Anthony
AU  - Pradhan, Deepak
AU  - Sterman, Daniel H.
AU  - Weiden, Michael
AU  - Hegu, Adriana
AU  - Evans, Laura
AU  - Uyeki, Timothy M.
AU  - Clemente, Jose C.
AU  - De wit, Emmie
AU  - Schmidt, Ann Marie
AU  - Shopsin, Bo
AU  - Desvignes, Ludovic
AU  - Wang, Chan
AU  - Li, Huilin
AU  - Zhang, Bin
AU  - Forst, Christian V.
AU  - Koide, Shohei
AU  - Stapleford, Kenneth A.
AU  - Khanna, Kamal M.
AU  - Ghedin, Elodie
AU  - Segal, Leopoldo N.
TI  - Microbial signatures in the lower airways of mechanically ventilated COVID19 patients associated with poor clinical outcome
AID  - 10.1101/2021.02.23.21252221
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.23.21252221
4099  - http://medrxiv.org/content/early/2021/02/26/2021.02.23.21252221.short
4100  - http://medrxiv.org/content/early/2021/02/26/2021.02.23.21252221.full
AB  - Mortality among patients with COVID-19 and respiratory failure is high and there are no known lower airway biomarkers that predict clinical outcome. We investigated whether bacterial respiratory infections and viral load were associated with poor clinical outcome and host immune tone. We obtained bacterial and fungal culture data from 589 critically ill subjects with COVID-19 requiring mechanical ventilation. On a subset of the subjects that underwent bronchoscopy, we also quantified SARS-CoV-2 viral load, analyzed the microbiome of the lower airways by metagenome and metatranscriptome analyses and profiled the host immune response. We found that isolation of a hospital-acquired respiratory pathogen was not associated with fatal outcome. However, poor clinical outcome was associated with enrichment of the lower airway microbiota with an oral commensal (Mycoplasma salivarium), while high SARS-CoV-2 viral burden, poor anti-SARS-CoV-2 antibody response, together with a unique host transcriptome profile of the lower airways were most predictive of mortality. Collectively, these data support the hypothesis that 1) the extent of viral infectivity drives mortality in severe COVID-19, and therefore 2) clinical management strategies targeting viral replication and host responses to SARS-CoV-2 should be prioritized.Competing Interest StatementThe authors have declared no competing interest.Funding StatementR37 CA244775 (LNS, NCI/NIH); R01 HL125816 (LNS, SBK, NHLBI/NIH); Colton Pilot Project Grant (LNS, LA, SBL, KK); UWSC12030 (LNS, RP, LE, CDC Foundation); PACT grant (LNS, FNIH); R21 AI158997 (SK); R01 AI143861 (KMK, NIAID/NIH); R01 AI143861-02S1 (KMK, NIAID/NIH); R01 DK110014 (HL and CW, NIDDK/NIH); P20 CA252728 (CW and HL, NCI/NIH) American Association for Cancer Research Grant (HP/LNS); The Genome Technology Center is partially supported by the Cancer Center Support Grant P30CA016087 at the Laura and Isaac Perlmutter Cancer Center (AH, AT); FAMRI Young Clinical Scientist Award (BGW), Stony Wold-Herbert Fund Grant-in-Aid/Fellowship (IS, CB). This work was supported in part by the Division of Intramural Research (DIR) of the NIAID/NIH (EG, EDW). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Board of New York UniversityAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequencing data are available in NCBI's Sequence Read Archive at the links provided bellow. https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA688510 https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA687506